Drugs Information:
Viloxazine
Basic Information
|
||
ID | DDInter2136 | |
Drug Type | small molecule | |
Molecular Formula | C13H19NO3 | |
Molecular Weight | 237.299 | |
CAS Number | 46817-91-8 | |
Description | Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these therapeutic indications. In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985] | |
ATC Classification | N06AX09 | |
IUPAC Name | 2-[(2-ethoxyphenoxy)methyl]morpholine | |
InChI | YWPHCCPCQOJSGZ-UHFFFAOYSA-N | |
Canonical SMILES | CCOC1=CC=CC=C1OCC1CNCCO1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL |
Interactions with
Viloxazine
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|